These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 35284802)

  • 1. Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
    von Tresckow J; Heyl N; Robrecht S; Giza A; Aldaoud A; Schlag R; Klausmann M; Linde H; Stein W; Schwarzer A; Fischer K; Cramer P; Eichhorst B; Hallek M; Fink AM
    Ann Hematol; 2023 Nov; 102(11):3083-3090. PubMed ID: 37358640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib.
    Yasuda H; Tomizawa Y; Harada S; Sasaki M; Komatsu N; Ando J; Hattori N; Ando M
    Heliyon; 2022 Oct; 8(10):e10928. PubMed ID: 36247137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.
    Alu A; Lei H; Han X; Wei Y; Wei X
    J Hematol Oncol; 2022 Oct; 15(1):138. PubMed ID: 36183125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861.
    Panjideh H; Niesler N; Weng A; Fuchs H
    Toxins (Basel); 2022 Jul; 14(7):. PubMed ID: 35878216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
    Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
    Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.
    Jean GW; Comeau JM
    Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
    Kutsch N; Pallasch C; Tausch E; Böhme V; Ritgen M; Liersch R; Wacker A; Jacobs G; Trappe RU; Dreger P; Fischer K; Fink AM; Stilgenbauer S; Zhai S; Li B; Jürgensmeier JM; Rajakumaraswamy N; Bhargava P; Hallek M; Eichhorst BF
    Hemasphere; 2022 Apr; 6(4):e692. PubMed ID: 35284802
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
    Kutsch N; Pallasch C; Decker T; Hebart H; Chow KU; Graeven U; Kisro J; Kroeber A; Tausch E; Fischer K; Fink AM; Wendtner CM; Ritgen M; Stilgenbauer S; Zhang D; Li B; Jürgensmeier JM; Rajakumaraswamy N; Bhargava P; Hallek M; Eichhorst B
    Hemasphere; 2022 Jun; 6(6):e729. PubMed ID: 35747845
    [No Abstract]   [Full Text] [Related]  

  • 9. Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies.
    Kittai AS; Best S; Thurlow B; Lam V; Hashiguchi T; Goodyear S; Persky DO; Okada C; Park B; Spurgeon SE; Danilov AV
    Haematologica; 2021 Jul; 106(7):2022-2025. PubMed ID: 33504141
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
    Munakata W; Ando K; Hatake K; Fukuhara N; Kinoshita T; Fukuhara S; Shirasugi Y; Yokoyama M; Ichikawa S; Ohmachi K; Gion N; Aoi A; Tobinai K
    Cancer Sci; 2019 May; 110(5):1686-1694. PubMed ID: 30815927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
    Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
    Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.
    Tam CS; Quach H; Nicol A; Badoux X; Rose H; Prince HM; Leahy MF; Eek R; Wickham N; Patil SS; Huang J; Prathikanti R; Cohen A; Elstrom R; Reed W; Schneider J; Flinn IW
    Blood Adv; 2020 Oct; 4(19):4802-4811. PubMed ID: 33022066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
    Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
    Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
    Danilov AV; Herbaux C; Walter HS; Hillmen P; Rule SA; Kio EA; Karlin L; Dyer MJS; Mitra SS; Yi PC; Humeniuk R; Huang X; Zhou Z; Bhargava P; Jürgensmeier JM; Fegan CD
    Clin Cancer Res; 2020 Jun; 26(12):2810-2818. PubMed ID: 32156743
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.